Fludara (Oral) Phase II Study for Indolent Lymphoma
To assess the antitumor effect and safety of Fludara in patients with indolent lymphoma.
Lymphoma
DRUG: Fludarabine Phosphate (Fludara)
Best overall response rate; Antitumor effect, at screening and re-evaluation, at 4th week or at the time of discontinuation of treatment cycles 1, 3 and 6, and at 12th week after last observation of last treatment cycle
CR rate, after last observation of last treatment cycle|Time to treatment failure, after last observation of last treatment cycle|Overall survival, after last observation of last treatment cycle|Adverse events collection, after last observation of last treatment cycle
As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer Schering Pharma AG, Germany.